Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)

SHE:300573 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,194	1,924	1,440	1,227	1,024	683.22
Other Revenue	20.53	19.49	27.86	23.2	3.6	5.46
Revenue	2,214	1,943	1,468	1,250	1,028	688.68
Revenue Growth (YoY)	32.29%	32.42%	17.42%	21.59%	49.26%	26.96%
Cost of Revenue	460.41	424.53	340.36	270.08	229.01	187.87
Gross Profit	1,754	1,519	1,127	979.78	798.91	500.81
Selling, General & Admin	909.7	875.78	689.8	595.39	456.54	321.34
Research & Development	233.72	220.66	167.3	145.61	88.45	63.19
Other Operating Expenses	25.09	10.68	7.16	6.66	13.8	3.14
Operating Expenses	1,169	1,110	867.29	748.58	558.6	388.71
Operating Income	585.01	408.42	259.93	231.2	240.31	112.1
Interest Expense	-6.25	-5.71	-1.44	-0.94	-5.99	-5.94
Interest & Investment Income	3.4	5.66	7.91	9.93	3.98	0.22
Currency Exchange Gain (Loss)	-1.74	-0.11	0.2	-0.09	-0.13	-0.02
Other Non Operating Income (Expenses)	5.97	-2.11	-1.15	-19.31	-1.05	-3.74
EBT Excluding Unusual Items	586.38	406.15	265.45	220.79	237.12	102.62
Gain (Loss) on Sale of Investments	-	-0.02	-	-	-	-
Gain (Loss) on Sale of Assets	-1.06	-0.98	-0.04	0.42	5.16	-0.08
Asset Writedown	-14.05	-14.05	-	-0	-0	-
Other Unusual Items	8.14	3.94	-0.42	12.51	1.26	-
Pretax Income	579.41	395.03	264.99	233.72	243.54	102.54
Income Tax Expense	75.85	56.97	24.96	22.03	34.43	9.08
Earnings From Continuing Operations	503.57	338.06	240.04	211.68	209.11	93.46
Minority Interest in Earnings	-	-	-	-	-14.41	-5.48
Net Income	503.57	338.06	240.04	211.68	194.7	87.98
Net Income to Common	503.57	338.06	240.04	211.68	194.7	87.98
Net Income Growth	56.58%	40.84%	13.39%	8.72%	121.31%	145.11%
Shares Outstanding (Basic)	244	244	244	241	224	221
Shares Outstanding (Diluted)	246	245	244	241	224	225
Shares Change (YoY)	-0.06%	0.70%	0.96%	7.45%	-0.30%	2.88%
EPS (Basic)	2.06	1.39	0.99	0.88	0.87	0.40
EPS (Diluted)	2.05	1.38	0.99	0.88	0.87	0.39
EPS Growth	56.68%	39.86%	12.32%	1.19%	120.40%	139.95%
Free Cash Flow	319.96	218.27	55.61	-12.96	211.9	14.01
Free Cash Flow Per Share	1.30	0.89	0.23	-0.05	0.94	0.06
Dividend Per Share	1.414	1.071	1.888	0.547	0.237	0.091
Dividend Growth	-24.79%	-43.25%	245.37%	130.73%	160.04%	99.78%
Gross Margin	79.21%	78.16%	76.81%	78.39%	77.72%	72.72%
Operating Margin	26.42%	21.02%	17.71%	18.50%	23.38%	16.28%
Profit Margin	22.74%	17.39%	16.36%	16.94%	18.94%	12.78%
Free Cash Flow Margin	14.45%	11.23%	3.79%	-1.04%	20.61%	2.03%
EBITDA	675.73	499.83	340.3	297.23	297.55	157.61
EBITDA Margin	30.52%	25.72%	23.19%	23.78%	28.95%	22.88%
D&A For EBITDA	90.72	91.42	80.38	66.03	57.24	45.51
EBIT	585.01	408.42	259.93	231.2	240.31	112.1
EBIT Margin	26.42%	21.02%	17.71%	18.50%	23.38%	16.28%
Effective Tax Rate	13.09%	14.42%	9.42%	9.43%	14.14%	8.86%
Revenue as Reported	2,214	1,943	1,468	1,250	1,028	688.68
Advertising Expenses	-	42.52	13.81	13	5.22	6.89

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.